Literature DB >> 12202982

Chromosome 3p and breast cancer.

Qifeng Yang1, Goro Yoshimura, Ichiro Mori, Takeo Sakurai, Kennichi Kakudo.   

Abstract

Solid tumors in humans are now believed to develop through a multistep process that activates oncogenes and inactivates tumor suppressor genes. Loss of heterozygosity at chromosomes 3p25, 3p22-24, 3p21.3, 3p21.2-21.3, 3p14.2, 3p14.3, and 3p12 has been reported in breast cancers. Retinoid acid receptor beta2 (3p24), thyroid hormone receptor beta1 (3p24.3), Ras association domain family 1A (3p21.3), and the fragile histidine triad gene (3p14.2) have been considered as tumor suppressor genes (TSGs) for breast cancers. Epigenetic change may play an important role for the inactivation of these TSGs. Screens for promoter hypermethylation may be able to identify other TSGs in chromosome 3p. Alternatively, use of an "epigenetic modifier" may enhance the response to another type of agent for breast cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12202982     DOI: 10.1007/s100380200064

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  10 in total

1.  KLHDC8B in Hodgkin lymphoma and possibly twinning.

Authors:  Andrew E Timms; Marshall S Horwitz
Journal:  Commun Integr Biol       Date:  2010-03

2.  Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells.

Authors:  Stephen J Salipante; Matthew E Mealiffe; Jeremy Wechsler; Maxwell M Krem; Yajuan Liu; Shinae Namkoong; Govind Bhagat; Tomas Kirchhoff; Kenneth Offit; Henry Lynch; Peter H Wiernik; Mikhail Roshal; Mary Lou McMaster; Margaret Tucker; Jonathan R Fromm; Lynn R Goldin; Marshall S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

Review 3.  Tumor suppressor FUS1 signaling pathway.

Authors:  Lin Ji; Jack A Roth
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

4.  Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.

Authors:  Rahul Bhagat; Sandeep Sriram Kumar; Shilpa Vaderhobli; Chennagiri S Premalata; Venkateshaiah Reddihalli Pallavi; Gawari Ramesh; Lakshmi Krishnamoorthy
Journal:  Tumour Biol       Date:  2014-06-10

5.  Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Maxwell M Krem; Stephen J Salipante; Marshall S Horwitz
Journal:  Cell Cycle       Date:  2010-03-02       Impact factor: 4.534

6.  Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.

Authors:  Zhaohui Wang; Lili Li; Xianwei Su; Zifen Gao; Gopesh Srivastava; Paul G Murray; Richard Ambinder; Qian Tao
Journal:  J Transl Med       Date:  2012-10-11       Impact factor: 5.531

7.  The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs.

Authors:  Zina Jeyapalan Rutnam; William W Du; Weining Yang; Xiangling Yang; Burton B Yang
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

8.  Phospholipase Cδ1 suppresses cell migration and invasion of breast cancer cells by modulating KIF3A-mediated ERK1/2/β- catenin/MMP7 signalling.

Authors:  Qing Shao; Xinrong Luo; Dejuan Yang; Can Wang; Qiao Cheng; Tingxiu Xiang; Guosheng Ren
Journal:  Oncotarget       Date:  2017-04-25

9.  TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis.

Authors:  Fengqiong Liu; Ruijie Gong; Baochang He; Fa Chen; Zhijian Hu
Journal:  BMC Cancer       Date:  2018-09-15       Impact factor: 4.430

10.  LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1.

Authors:  Di Zhang; Song Li; Wenbin Yu; Cheng Chen; Teng Liu; Yiting Sun; Zeyi Zhao; Lian Liu
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.